Search
Ulcerative Colitis Paid Clinical Trials in North Carolina
A listing of 18 Ulcerative Colitis clinical trials in North Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 18
The state of North Carolina currently has 18 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
Featured Trial
Ulcerative colitis (UC) Trials
Recruiting
Ulcerative colitis (UC) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Ulcerative colitis (UC)
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Ulcerative Colitis Study For Adolescents
Recruiting
We are looking for children 2 to 17 years old diagnosed with ulcerative colitis to join our latest study to help us further develop our knowledge of UC and discover potential new medication options for those whose previous treatment has not been successful.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Ulcerative Colitis Chronic Moderate
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Featured Trial
Ulcerative Colitis Clinical Trial
Recruiting
Are you or someone you know struggling with Ulcerative Colitis? A clinical study in the area is currently open to enroll participants. Eligible adults will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Ulcerative Colitis Chronic Mild
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Carolina Digestive Diseases, Greenville, North Carolina
Conditions: Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Sc... Read More
Gender:
All
Ages:
Between 16 years and 75 years
Trial Updated:
06/21/2024
Locations: Carolina Digestive Diseases and Endoscopy Center ( Site 3809), Greenville, North Carolina
Conditions: Ulcerative Colitis
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment.
All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone fo... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: University of North Carolina, Chapel Hill, North Carolina +1 locations
Conditions: Ulcerative Colitis
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed.
Lutikizumab is an investigational product being developed for the treatment of UC. Participants are pla... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: DJL Clinical Research, PLLC /ID# 259465, Charlotte, North Carolina
Conditions: Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Digestive Health Partners - Research Department, Asheville, North Carolina +2 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed.
Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/12/2024
Locations: Levine Children's Hospital /ID# 250131, Charlotte, North Carolina
Conditions: Ulcerative Colitis
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled.
All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/05/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
05/31/2024
Locations: Duke Medical Plaza North Duke Street, Durham, North Carolina +4 locations
Conditions: Ulcerative Colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2024
Locations: Clinical & Translational Research Center (CTRC), Chapel Hill, North Carolina
Conditions: Ulcerative Colitis
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte, North Carolina +2 locations
Conditions: Ulcerative Colitis
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed.
ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approx... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Atrium Health /ID# 249273, Charlotte, North Carolina
Conditions: Ulcerative Colitis
ABTECT - Maintenance
Recruiting
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/23/2024
Locations: Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte, North Carolina +3 locations
Conditions: Ulcerative Colitis
1 - 12 of 18